Compound ID | 2894

Update compound information

TBA-7371

Class: Small molecule antibacterial agent

Details of activity: Active against Mycobacterium tuberculosis; DprE1 inhibitor
Description: Synthetic compound from scaffold morphing of imidazopyridine compound; no cytotoxicity at 100 uM
Institute where first reported: Astra Zeneca and TB Alliance
Year first mentioned: 2014
Highest developmental phase: Phase 2 (NCT04176250)
Development status: Active (as of 2025)
Chemical structure(s):
Click here for structure editor
Molecular weight: 355.39
Iso. SMILES: CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1
InChI Key: VDRYGTNDKXIPSK-UHFFFAOYSA-N
Can. SMILES: CC1=CN=C2C(=CN(CC3=NC=NC(=C3C)OC)C2=C1)C(=O)NCCO
InChI: InChI=1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/72792692
Guide to Pharmacology: TBA-7371
Citations:
  • https://journals.asm.org/doi/10.1128/aac.03233-14
  • https://journals.asm.org/doi/10.1128/aac.00583-21

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.